Filing Details

Accession Number:
0001209191-15-051540
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-06-09 18:13:37
Reporting Period:
2015-06-05
Filing Date:
2015-06-09
Accepted Time:
2015-06-09 18:13:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
911326 Synageva Biopharma Corp GEVA Biological Products, (No Disgnostic Substances) (2836) 561808663
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1559209 Glen Williams 33 Hayden Ave
Lexington MA 02421
Svp, Technical Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-06-05 25,500 $0.00 25,968 No 4 A Direct
Common Stock Acquisiton 2015-06-08 833 $40.32 26,801 No 4 M Direct
Common Stock Acquisiton 2015-06-08 833 $57.56 27,634 No 4 M Direct
Common Stock Acquisiton 2015-06-08 11,250 $80.35 38,884 No 4 M Direct
Common Stock Disposition 2015-06-08 10,396 $214.72 28,488 No 4 S Direct
Common Stock Disposition 2015-06-08 2,520 $215.72 25,968 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2015-06-08 833 $0.00 833 $40.32
Common Stock Stock Option (Right to Buy) Disposition 2015-06-08 833 $0.00 833 $57.56
Common Stock Stock Option (Right to Buy) Disposition 2015-06-08 11,250 $0.00 11,250 $80.35
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
20,002 2023-06-06 No 4 M Direct
13,334 2022-10-04 No 4 M Direct
33,750 2024-06-04 No 4 M Direct
Footnotes
  1. Award of Restricted Stock Units under the 2014 Equity Incentive Plan. Vests (x) 25% on June 5, 2016 and (y) 12.5% per six months thereafter.
  2. The stock option exercise and sale of shares of the Company's common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 2, 2015.
  3. 25% of the total number of shares subject to the option vest and become exercisable on 06/06/2014 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter.
  4. 25% of the total number of shares subject to the option vest and become exercisable on 09/24/2013 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter.
  5. 25% of the total number of shares subject to the option vest and become exercisable on 06/04/2015 and 1/36 of the remainder of the shares subject to the option shall vest and become exercisable monthly thereafter
  6. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $214.35 to $215.33. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
  7. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $215.38 to $216.17. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.